1. Advances in the pharmacological management of acute myeloid leukemia in adults. (2nd September 2022) Authors: Numan, Yazan; Abaza, Yasmin; Altman, Jessica K; Platanias, Leonidas C Journal: Expert opinion on pharmacotherapy Issue: Volume 23:Number 13(2022) Page Start: 1535 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study. Issue 4 (April 2023) Authors: Garcia-Manero, Guillermo; Goldberg, Aaron D; Winer, Eric S; Altman, Jessica K; Fathi, Amir T; Odenike, Olatoyosi; Roboz, Gail J; Sweet, Kendra; Miller, Crystal; Wennborg, Anders; Hickman, Denice K; Kanagal-Shamanna, Rashmi; Kantarjian, Hagop; Lancet, Jeffrey; Komrokji, Rami; Attar, Eyal C; Sallma... Journal: Lancet Issue: Volume 10:Issue 4(2023) Page Start: e272 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Next generation of mammalian target of rapamycin inhibitors for the treatment of cancer. (September 2013) Authors: Nelson, Valerie; Altman, Jessica K; Platanias, Leonidas C Journal: Expert opinion on investigational drugs Issue: Volume 22:Number 6(2013:Jun.) Page Start: 715 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Next generation of mammalian target of rapamycin inhibitors for the treatment of cancer. (September 2013) Authors: Nelson, Valerie; Altman, Jessica K; Platanias, Leonidas C Journal: Expert opinion on investigational drugs Issue: Volume 22:Number 6(2013:Jun.) Page Start: 715 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. Issue 7 (July 2018) Authors: Cortes, Jorge; Perl, Alexander E; Döhner, Hartmut; Kantarjian, Hagop; Martinelli, Giovanni; Kovacsovics, Tibor; Rousselot, Philippe; Steffen, Björn; Dombret, Hervé; Estey, Elihu; Strickland, Stephen; Altman, Jessica K; Baldus, Claudia D; Burnett, Alan; Krämer, Alwin; Russell, Nigel; Shah, Neil P;... Journal: Lancet oncology Issue: Volume 19:Issue 7(2018) Page Start: 889 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study. Issue 8 (August 2017) Authors: Perl, Alexander E; Altman, Jessica K; Cortes, Jorge; Smith, Catherine; Litzow, Mark; Baer, Maria R; Claxton, David; Erba, Harry P; Gill, Stan; Goldberg, Stuart; Jurcic, Joseph G; Larson, Richard A; Liu, Chaofeng; Ritchie, Ellen; Schiller, Gary; Spira, Alexander I; Strickland, Stephen A; Tibes, Ra... Journal: Lancet oncology Issue: Volume 18:Issue 8(2017:Aug.) Page Start: 1061 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Targeted therapy of acute myeloid leukemia. Issue 4 (April 2015) Authors: Carneiro, Benedito A; Altman, Jessica K; Kaplan, Jason B; Ossenkoppele, Gert; Swords, Ronan; Platanias, Leonidas C; Giles, Francis J Journal: Expert review of anticancer therapy Issue: Volume 15:Issue 4(2015) Page Start: 399 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗